Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound may spot silent joint damage in mild hemophilia

NCT ID NCT07719647

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This study uses ultrasound to examine the joints of adults with mild hemophilia, a group that often goes understudied. Researchers will scan six joints (ankles, knees, elbows) to look for early signs of damage that may not cause symptoms yet. The goal is to see how common joint problems are in mild hemophilia and whether they relate to blood clotting factor levels. The findings could help guide personalized care and education to protect joint health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better monitoring and earlier treatment for joint damage in people with mild hemophilia, potentially improving their quality of life.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may not change current care if no strong link between ultrasound findings and factor levels is found.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2027

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (≥18 years old) with congenital mild hemophilia, defined as historical coagulation factor level \>5% and \<40% (FVIII or FIX). * Affiliated with a social security system. * Provided written informed consent to participate in the study. Exclusion Criteria: * Patient on prophylactic treatment, defined as at least one of the following: o. ≥5 factor concentrate injections per month for a period of more than 6 months o. Treatment with emicizumab o. Last factor concentrate injection within the past 28 days * Patient with acquired hemophilia. * Patient with uncontrolled chronic rheumatologic disease, such as rheumatoid arthritis, inflammatory spondyloarthropathies, or microcrystalline arthritis. * Known pregnancy or breastfeeding. * Patient deprived of liberty or under legal guardianship or conservatorship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild hemophilia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthropathy hemophilia A hemophilia B mild hemophilia A mild hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild hemophilia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Necker Enfants malades

    Paris, Île-de-France Region, 75015, France